CNA:LSECentrica plc Analysis

Centri​ca’s shares are trading at 207 p, comfortably above the 20‑day SMA (≈195.7 p) and the 50‑day SMA (≈189.4 p), while the 200‑day SMA sits near 171.8 p, confirming a strong bullish trend. The MACD line remains positive (≈3.92) and above its signal (≈2.96), and the histogram is expanding, reinforcing upward momentum. RSI is perched at 69.5, indicating near‑overbought conditions but still below the classic 70 threshold, suggesting limited upside pressure for now. Volume has been decreasing, which may temper short‑term rallies, yet the stock’s beta of 0.48 and 30‑day volatility of 27 % point to relatively low market‑wide risk.
Fundamentally, the company posted a slight loss this year (trailing EPS –0.02) but forecasts a rebound with forward EPS of 0.149, yielding a forward P/E of 13.9 versus an industry average of 23.3, implying undervaluation. The DCF‑derived fair value of ~1,094 p translates to an upside of roughly 430 %, reinforcing the undervalued view. Cash balances (≈4.3 bn £) comfortably cover debt (≈2.86 bn £) and support a 2.66 % dividend yield with a modest 16.6 % payout ratio, making the dividend appear sustainable. Recent news highlights a pause on the share‑buyback programme to fund the Sizewell C nuclear project, signalling capital reallocation toward long‑term growth rather than short‑term price support. Overall, the blend of a solid dividend, low‑beta defensive profile, and strategic investment pipeline positions Centrica as a compelling buy for patient investors.